MGROF Company Profile and Key Details

MustGrow Biologics Corp. (OTC:MGROF) closed at $0.32 USD, gaining $0.02 (6.67%) from the previous close of $0.30. The stock is currently mid-range between its 52-week high and low $0.22 and $0.68. With a market capitalization of about $20.15 million, MustGrow Biologics Corp. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.33). Key stats such as the average daily volume over the past year has been around 4.21 thousand shares, in line with its 52-week average. Headquartered in Saskatoon, SK, MustGrow Biologics Corp. operates in the Basic Materials sector and the Agricultural Inputs industry. Led by CEO Corey J. Giasson, the company employs approximately 10 people and listed since November 21, 2019. MustGrow Biologics Corp., an agricultural biotechnology company headquartered in Saskatoon, Canada, since its incorporation in 2014 (and known as Duport Capital Ltd. until March 2018), specializes in developing and commercializing natural pest and weed control solutions derived from mustard seed.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Average 10-day trading volume of 3.91 thousand shares is below the 3-month average of 7.01 thousand, indicating normal recent market interest.

MustGrow Biologics Corp. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended April 29, 2026, missed forecasts by 78.57%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in April 23, 2025.

Valuation shows MustGrow Biologics Corp. trading at a premium to the broader market with a P/E of -4.9.

Our AI price prediction model suggests that MustGrow Biologics Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

MustGrow Biologics Corp. trades at a P/E ratio of -4.9, slightly below the S&P 500 average, with a price-to-sales ratio of 8.18 and a price-to-book ratio of 5.25 trading at moderately above to book value. The P/FCF stands at -6.02, also above market averages.